Clinical and Experimental Nephrology

, Volume 22, Issue 3, pp 550–561 | Cite as

Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study

  • Satoshi Minami
  • Takayuki Hamano
  • Hirotsugu Iwatani
  • Masayuki Mizui
  • Yoshiki Kimura
  • Yoshitaka Isaka
Original article
  • 288 Downloads

Abstract

Background

Tolvaptan (TLV) promotes aquaresis; however, little is known about its effect on solute excretion in chronic kidney disease (CKD).

Methods

We retrospectively studied CKD patients with decompensated heart failure (HF) or those with autosomal dominant polycystic kidney disease (ADPKD) receiving TLV. Patients with an increased urine volume of more than twice of daily variance were defined as “responders” in HF. We compared the ability of the urinary osmolality (U-OSM) change and urinary creatinine concentration ([U-Cr]) change to discriminate “responders”. The fractional excretion of sodium (FeNa) and urea nitrogen (FeUN), and blood urea nitrogen (BUN) were monitored.

Results

In 30 responders among 53 HF patients, TLV increased FeUN significantly from 36.1 to 44.2% after starting TLV, but not FeNa. Since U-OSM is determined partially by urinary UN concentration, the decrease of [U-Cr] after treatment outperformed the U-OSM decrement to discriminate responders, as shown in receiver operating characteristic curve analysis and significantly higher net reclassification index. In 13 ADPKD patients, TLV increased FeUN (34.8, 47.3%, p = 0.02), and significant decrease of BUN by 2.3 (95% confidence interval 0.4–4.2) mg/dL was observed even 3 months after the intervention. Systolic blood pressure decreased significantly by 14.2 (95% confidence interval 4.0–24.4) mmHg along with the increase in FeNa, leading to reduced dosage of antihypertensives in 6 patients.

Conclusion

TLV promotes the excretion of sodium and urea. The change in [U-Cr] is useful for early discrimination of responders. Hypotension should be carefully monitored during high-dose TLV therapy.

Keywords

Autosomal dominant polycystic kidney disease Chronic kidney disease Decompensated heart failure Sodium excretion Tolvaptan Urea excretion 

Notes

Acknowledgements

This study received no specific external funding.

Compliance with ethical standards

Conflict of interest

HI., T.H., and Y.I. have received grant support and lecture fees from Otsuka Pharmaceutical Company, which sells tolvaptan in Japan. The company played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; nor in the preparation, review, or approval of the manuscript.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval number 16322) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

We provided all individual patients with the option to opt out of participation.

Supplementary material

10157_2017_1475_MOESM1_ESM.pdf (161 kb)
Supplementary material 1 (PDF 161 kb)

References

  1. 1.
    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407–18.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9:1323–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Wang X, Gattone V 2nd, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol. 2005;16:846–51.CrossRefPubMedGoogle Scholar
  4. 4.
    Perucca J, Bichet DG, Bardoux P, Bouby N, Bankir L. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists. J Am Soc Nephrol. 2008;19:1721–31.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ecelbarger CA, Kim GH, Terris J, Masilamani S, Mitchell C, Reyes I, et al. Vasopressin-mediated regulation of epithelial sodium channel abundance in rat kidney. Am J Physiol Renal Physiol. 2000;279:F46–53.CrossRefPubMedGoogle Scholar
  6. 6.
    Sun A, Grossman EB, Lombardi M, Hebert SC. Vasopressin alters the mechanism of apical Cl entry from Na+:Cl to Na+:K+:2Cl cotransport in mouse medullary thick ascending limb. J Membr Biol. 1991;120:83–94.CrossRefPubMedGoogle Scholar
  7. 7.
    Bankir LT, Trinh-Trang-Tan MM. Renal urea transporters Direct and indirect regulation by vasopressin. Exp Physiol. 2000;85:243s–52s.CrossRefPubMedGoogle Scholar
  8. 8.
    Kim SR, Hasunuma T, Sato O, Okada T, Kondo M, Azuma J. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers. Cardiovasc Drugs Ther. 2011;25(Suppl 1):S5–17.CrossRefPubMedGoogle Scholar
  9. 9.
    Kajimoto K, Abe T. Blood urea nitrogen as a marker of the acute response to addition of tolvaptan to standard therapy in patients hospitalized for acute heart failure syndromes. Int J Cardiol. 2014;177:589–91.CrossRefPubMedGoogle Scholar
  10. 10.
    Gilotra NA, Russell SD. Arginine vasopressin as a target in the treatment of acute heart failure. World J Cardiol. 2014;6:1252–61.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Konstam MA, Gheorghiade M, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319–31.CrossRefPubMedGoogle Scholar
  12. 12.
    Matsuzaki M, Hori M, Izumi T, Fukunami M, Tolvaptan I. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011;25(Suppl 1):S33–45.CrossRefPubMedGoogle Scholar
  13. 13.
    Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients. Circ J. 2013;77:397–404.CrossRefPubMedGoogle Scholar
  14. 14.
    Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, et al. Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab. 2005;23:97–104.CrossRefPubMedGoogle Scholar
  15. 15.
    von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573–7.CrossRefGoogle Scholar
  16. 16.
    Japanese Society of Nephrology. Evidence-based Clinical Practice Guideline for CKD 2013. Clin Exp Nephrol. 2014;18:346–423.CrossRefGoogle Scholar
  17. 17.
    Mori T, Oba I, Koizumi K, Kodama M, Shimanuki M, Tanno M, et al. Beneficial role of tolvaptan in the control of body fluids without reductions in residual renal function in patients undergoing peritoneal dialysis. Adv Perit Dial. 2013;29:33–7.PubMedGoogle Scholar
  18. 18.
    Afsar B, Ortiz A, Covic A, Solak Y, Goldsmith D, Kanbay M. Focus on renal congestion in heart failure. Clin Kidney J. 2016;9:39–47.CrossRefPubMedGoogle Scholar
  19. 19.
    Schrier RW. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2009;20:1888–93.CrossRefPubMedGoogle Scholar
  20. 20.
    Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, et al. Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med. 2014;371:2255–66.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med. 2005;142:342–51.CrossRefPubMedGoogle Scholar
  22. 22.
    Rinkel GJ. Natural history, epidemiology and screening of unruptured intracranial aneurysms. J Neuroradiol. 2008;35:99–103.CrossRefPubMedGoogle Scholar
  23. 23.
    Yang B, Bankir L. Urea and urine concentrating ability: new insights from studies in mice. Am J Physiol Renal Physiol. 2005;288:F881–96.CrossRefPubMedGoogle Scholar
  24. 24.
    Fenton RA, Flynn A, Shodeinde A, Smith CP, Schnermann J, Knepper MA. Renal phenotype of UT-A urea transporter knockout mice. J Am Soc Nephrol. 2005;16:1583–92.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Gheorghiade M, Konstam MA, Burnett JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332–43.CrossRefPubMedGoogle Scholar
  26. 26.
    Koeth RA, Kalantar-Zadeh K, Wang Z, Fu X, Tang WH, Hazen SL. Protein carbamylation predicts mortality in ESRD. J Am Soc Nephrol. 2013;24:853–61.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Drechsler C, Kalim S, Wenger JB, Suntharalingam P, Hod T, Thadhani RI, et al. Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease. Kidney Int. 2015;87:1201–8.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Kalim S, Karumanchi SA, Thadhani RI, Berg AH. Protein carbamylation in kidney disease: pathogenesis and clinical implications. Am J Kidney Dis. 2014;64:793–803.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Pietrement C, Gorisse L, Jaisson S, Gillery P. Chronic increase of urea leads to carbamylated proteins accumulation in tissues in a mouse model of CKD. PLoS One. 2013;8:e82506.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Fenton RA, Chou CL, Stewart GS, Smith CP, Knepper MA. Urinary concentrating defect in mice with selective deletion of phloretin-sensitive urea transporters in the renal collecting duct. Proc Natl Acad Sci USA. 2004;101:7469–74.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Li F, Lei T, Zhu J, Wang W, Sun Y, Chen J, et al. A novel small-molecule thienoquinolin urea transporter inhibitor acts as a potential diuretic. Kidney Int. 2013;83:1076–86.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2017

Authors and Affiliations

  1. 1.Department of NephrologyOsaka University Graduate School of MedicineSuitaJapan
  2. 2.Department of Comprehensive Kidney Disease ResearchOsaka University Graduate School of MedicineSuitaJapan
  3. 3.Department of NephrologyNational Hospital Organization Osaka National HospitalOsakaJapan

Personalised recommendations